

NHS organisation statement template

Thank you for agreeing to give us your views on the technology and the way it should be used in the NHS.

Primary Care Trusts (PCTs) provide a unique perspective on the technology, which is not typically available from the published literature. NICE believes it is important to involve NHS organisations that are responsible for commissioning and delivering care in the NHS in the process of making decisions about how technologies should be used in the NHS.

To help you give your views, we have provided a template. The questions are there as prompts to guide you. You do not have to answer every question. Short, focused answers, giving a PCT perspective on the issues you think the committee needs to consider, are what we need.

About you

Your name: XXXXXXXXXX

Name of your organisation [Medway PCT sponsering Health Priority Setting Unit](#)

Please indicate your position in the organisation:

- commissioning services for the PCT in general?
- commissioning services for the PCT specific to the condition for which NICE is considering this technology?
- responsible for quality of service delivery in the PCT (e.g. medical director, public health director, director of nursing)?
- a specialist in the treatment of people with the condition for which NICE is considering this technology?
- a specialist in the clinical evidence base that is to support the technology (e.g. participation in clinical trials for the technology)?
- other (please specify) [advising commissioners on high cost drug issues](#)

What is the expected place of the technology in current practice?

How is the condition currently treated in the NHS? Is there significant geographical variation in current practice? Are there differences in opinion between professionals as to what current practice should be? What are the current alternatives (if any) to the technology, and what are their respective advantages and disadvantages?

There is some variation but from initial consultees interviews there does seem to be availability and use of infliximab in acute severe UC

To what extent and in which population(s) is the technology being used in your local health economy?

- is there variation in how it is being used in your local health economy?
- is it always used within its licensed indications? If not, under what circumstances does this occur?
- what is the impact of the current use of the technology on resources?
- what is the outcome of any evaluations or audits of the use of the technology?

- what is your opinion on the appropriate use of the technology?

Not within licensed indications but usually 3 doses.
Some variation in availability

Potential impact on the NHS if NICE recommends the technology

What impact would the guidance have on the delivery of care for patients with this condition?

If NICE recommends it as a maintenance therapy the cost implications will be significant.

In what setting should/could the technology be used – for example, primary or secondary care, specialist clinics? Would there be any requirements for additional resources (for example, staff, support services, facilities or equipment)?

The current evidence base is not strong however clinician opinion is very much in favour of at least short term use.

Can you estimate the likely budget impact? If this is not possible, please comment on what factors should be considered (for example, costs, and epidemiological and clinical assumptions).

In most trusts it is currently being used for other conditions so facilities already available.

In acute situation first does likely to be given when patient is in-patient so impact on staff/facilities not great.

Numbers of patients within each trust not likely to have major workload implications

Would implementing this technology have resource implications for other services (for example, the trade-off between using funds to buy more diabetes nurses versus more insulin pumps, or the loss of funds to other programmes)?

Would there be any need for education and training of NHS staff?

In most cases drug already being used for other conditions including Crohns so staff skills already there

Other Issues

Please include here any other issues you would like the Appraisal Committee to consider when appraising this technology.

Specifically a recommendation on dose regime as current use does not appear to be within the marketing authorisation

A large, empty rectangular box with a thin black border, intended for the user to enter their NHS organisation statement. It occupies the upper half of the page.